目的 探討復(fù)方苦參注射液聯(lián)合FOLFOX方案治療結(jié)直腸癌的臨床療效。方法 選取2010年3月-2014年2月新鄉(xiāng)市中心醫(yī)院治療的結(jié)直腸癌患者82例，隨機(jī)分為對(duì)照組和治療組，每組各41例。對(duì)照組給予FOLFOX方案：第1天靜脈滴注注射用奧沙利鉑，100 mg/m²加入到5%葡萄糖溶液250 mL中，滴注2 h；第1天靜脈滴注亞葉酸鈣注射液，400mg/m²加入到生理鹽水250 mL中，滴注2 h；第1天靜脈推注氟尿嘧啶注射液400 mg/m²，然后2 400 mg/m²靜脈持續(xù)滴注46 h。治療組在對(duì)照組基礎(chǔ)上靜脈滴注復(fù)方苦參注射液，20 mL加入生理鹽水中250 mL中，1次/d，連續(xù)治療7 d。兩組均以2周為一個(gè)療程，治療4個(gè)療程。觀察兩組的臨床療效，比較兩組外周血淋巴細(xì)胞亞群、不良反應(yīng)和生存率情況。結(jié)果 治療后，對(duì)照組和治療組的緩解率分別為39.02%、51.22%，疾病控制率分別為73.17%、87.80%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對(duì)照組外周血CD³⁺、CD⁴⁺、CD¹⁶⁺/CD⁵⁶⁺和CD⁴⁺/CD⁸⁺均顯著下降，CD⁸⁺顯著升高；治療組外周血CD³⁺、CD⁴⁺、CD¹⁶⁺/CD⁵⁶⁺和CD⁴⁺/CD⁸⁺均顯著升高，CD⁸⁺顯著下降，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。對(duì)照組和治療組的骨髓抑制率分別為56.10%、39.02%，胃腸道反應(yīng)發(fā)生率為58.54%、34.15%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。隨訪1、2、3年，對(duì)照組生存率分別為85.37%、68.29%、56.10%，治療組生存率分別為92.68%、80.49%、70.73%，兩組生存率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 復(fù)方苦參注射液聯(lián)合FOLFOX方案治療結(jié)直腸癌具有較好的臨床療效，可提高患者免疫功能，減少不良反應(yīng)，延長(zhǎng)生存期，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Compound Kushen Injection combined with FOLFOX regimen in treatment of colorectal cancer. Methods Patients (82 cases) with colorectal cancer in Xinxiang Central Hospital from March 2010 to February 2014 were randomly divided into control and treatment groups, and each group had 41 cases. Patients in the control group were given FOLFOX regimen. Patients in the control group were iv administered with Oxaliplatin for injection on day 1, 100 mg/m² added into 5% glucose solution (250 mL), infusion of 2 h. The patients in control group were iv administered with Calcium Folinate Injection at the first day, 400 mg/m² added into normal saline 250 mL, infusion of 2 h. And patients in the control group were iv injected with Fluorouracil Injection 400 mg/m² at the first day, then 2 400 mg/m² continuous iv infusion of 46 h. Patients in the treatment group were iv administered with Compound Kushen Injection on the basis of the control group, 20 mL added into normal saline 250 mL, once daily, treatment of 7 d. A course of treatment was 2 weeks, and patients in two groups were treated for 4 courses. After treatment, the clinical efficacies were evaluated, and lymphocyte subsets in peripheral blood, adverse reactions, and survival rate in two groups were compared. Results After treatment, the remission rate in the control and treatment groups were 39.02% and 51.22%, respectively, and the disease control rate in the control and treatment groups were 73.17% and 87.80%, respectively, and there was difference between two groups (P < 0.05). After treatment, CD³⁺, CD⁴⁺, CD¹⁶⁺/CD⁵⁶⁺, and CD⁴⁺/CD⁸⁺ in the control group were significantly decreased, but the CD⁸⁺ in the control group was significantly increased, and CD³⁺, CD⁴⁺, CD¹⁶⁺/CD⁵⁶⁺, and CD⁴⁺/CD⁸⁺ in the treatment group were significantly increased, but the CD⁸⁺ in the treatment group was significantly decreased, and there was difference between two groups (P < 0.05). The bone marrow inhibitory rates in the control and treatment groups were 56.10% and 39.02%, respectively, the gastrointestinal reaction rates in the control and treatment groups were 58.54% and 34.15%, respectively, and there was difference between two groups (P < 0.05). Followed up for 1, 2, and 3 years, the survival rates in the control group were 85.37%, 68.29%, and 56.10%, respectively, the survival rates in the treatment group were 92.68%, 80.49% and 70.73%, respectively, and there was difference between two groups (P < 0.05). Conclusion Compound Kushen Injection combined with FOLFOX regimen has clinical curative effect in treatment of colorectal cancer, and can improve immune function, reduce adverse reactions, and prolong survival times, which has a certain clinical application value.